HIGHLIGHTS
- who: IFNu03b3 gene expression signature from the Surgical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, Pharmaceuticals, Boston, Massachusetts. , Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. , Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia. , Medical Oncology, University of Iowa, Iowa City, Iowa. , Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas. have published the research: OPEN ACCESS, in the Journal: (JOURNAL) of 12/04/2023
- what: The authors propose that mavorixafor sensitizes the melanoma tumor microenvironment and enhances the activity of checkpoint . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.